Industry Experts

Bala Medicherla is an accomplished CMC analytics and bioanalytics leader with over 12 years of experience in the biotech and CDMO sectors, specializing in AAV gene therapy. He has successfully led the development of CMC analytical assays from early-stage clinical development (Phase 1) through to Phase 3 and commercial production.

Bala brings deep expertise in bioanalytical assay development to support preclinical research, GLP toxicology studies, and clinical trials. His functional leadership spans biomarker strategy, vector copy number (VCN) and biodistribution analysis, and immunogenicity assessments.

As a results-driven team leader with eight years of managerial experience, Bala has built and led high-performing teams, including Ph.D.-level scientists and group leaders. He has a proven track record of advancing analytical capabilities across a broad range of platforms, including AAV, adenovirus, lentivirus, virus-like particles (VLPs), and vaccine development.

Bala is recognized for his strategic mindset, technical rigor, and commitment to advancing gene therapies through innovative analytical solutions.